• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine

tetano

Editor, Senior Moderator
Cell Rep Med


. 2022 Apr 22;100631.
doi: 10.1016/j.xcrm.2022.100631. Online ahead of print.
Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine


Tomohiro Takano[SUP] 1 [/SUP], Miwa Morikawa[SUP] 2 [/SUP], Yu Adachi[SUP] 1 [/SUP], Kiyomi Kabasawa[SUP] 2 [/SUP], Nicolas Sax[SUP] 3 [/SUP], Saya Moriyama[SUP] 1 [/SUP], Lin Sun[SUP] 1 [/SUP], Masanori Isogawa[SUP] 1 [/SUP], Ayae Nishiyama[SUP] 1 [/SUP], Taishi Onodera[SUP] 1 [/SUP], Kazutaka Terahara[SUP] 1 [/SUP], Keisuke Tonouchi[SUP] 1 [/SUP], Masashi Nishimura[SUP] 2 [/SUP], Kentaro Tomii[SUP] 4 [/SUP], Kazuo Yamashita[SUP] 3 [/SUP], Takayuki Matsumura[SUP] 5 [/SUP], Masaharu Shinkai[SUP] 6 [/SUP], Yoshimasa Takahashi[SUP] 7 [/SUP]



Affiliations

Abstract

Two doses of Pfizer/BioNTech BNT162b2 mRNA vaccine elicit robust severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies with frequent adverse events. Here, by applying a high-dimensional immune profiling on 92 vaccinees, we identify six vaccine-induced immune dynamics that correlate with the amounts of neutralizing antibodies, the severity of adverse events, or both. The early dynamics of natural killer (NK)/monocyte subsets (CD16[SUP]+[/SUP] NK cells, CD56[SUP]high[/SUP] NK cells, and non-classical monocytes), dendritic cell (DC) subsets (DC3s and CD11c[SUP]-[/SUP] Axl[SUP]+[/SUP] Siglec-6[SUP]+[/SUP] [AS]-DCs), and NKT-like cells are revealed as the distinct cell correlates for neutralizing-antibody titers, severity of adverse events, and both, respectively. The cell correlates for neutralizing antibodies or adverse events are consistently associated with elevation of interferon gamma (IFN-γ)-inducible chemokines, but the chemokine receptors CCR2 and CXCR3 are expressed in distinct manners between the two correlates: vaccine-induced expression on the neutralizing-antibody correlate and constitutive expression on the adverse-event correlate. The finding may guide vaccine strategies that balance immunogenicity and reactogenicity.

Keywords: SARS-CoV-2; adverse events; cell dynamics; immune correlates; innate immunity; mRNA vaccine; neutralizing antibodies.
 
Back
Top Bottom